266 related articles for article (PubMed ID: 23156659)
21. Financial risk of the biotech industry versus the pharmaceutical industry.
Golec J; Vernon JA
Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
[TBL] [Abstract][Full Text] [Related]
22. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
Han E; Kim TH; Jeung MJ; Lee EK
Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
[TBL] [Abstract][Full Text] [Related]
23. Could Contracts between Pharmaceutical Firms and French Veterinarians Bias Prescription Behaviour: A Principal-Agency Theory Approach in the Context of Oligopolies.
Raboisson D; Ferchiou A; Corre T; Perez S; Sans P; Lhermie G; Dervillé M
Antibiotics (Basel); 2021 Feb; 10(2):. PubMed ID: 33578688
[TBL] [Abstract][Full Text] [Related]
24. Microcap pharmaceutical firms: linking drug pipelines to market value.
Beach R
J Health Care Finance; 2012; 39(2):82-92. PubMed ID: 23971143
[TBL] [Abstract][Full Text] [Related]
25. Current practice and perspectives in CRO oversight based on a survey performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
Hennig M; Hundt F; Busta S; Mikus S; Sanden PH; Sörgel A; Ruppert T
Ger Med Sci; 2017; 15():Doc02. PubMed ID: 28163667
[TBL] [Abstract][Full Text] [Related]
26. Choice of contracts in the British National Health Service: an empirical study.
Chalkley M; McVicar D
J Health Econ; 2008 Sep; 27(5):1155-67. PubMed ID: 18617283
[TBL] [Abstract][Full Text] [Related]
27. Biopharma CRO industry in China: landscape and opportunities.
Xia C; Gautam A
Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
[TBL] [Abstract][Full Text] [Related]
28. Big-pharmaceuticalisation: clinical trials and Contract Research Organisations in India.
Sariola S; Ravindran D; Kumar A; Jeffery R
Soc Sci Med; 2015 Apr; 131():239-46. PubMed ID: 25476783
[TBL] [Abstract][Full Text] [Related]
29. Clinical trials in India.
Maiti R; M R
Pharmacol Res; 2007 Jul; 56(1):1-10. PubMed ID: 17391981
[TBL] [Abstract][Full Text] [Related]
30. Use of performance standards in behavioral health carve-out contracts among Fortune 500 firms.
Merrick EL; Garnick DW; Horgan CM; Goldin D; Hodgkin D; Sciegaj M
Am J Manag Care; 1999 Jun; 5 Spec No():SP81-90. PubMed ID: 10538863
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the impact of the FDA's orphan drug designation on share prices of biotechnology companies.
Williamson J; Spicer AJ
Drug Discov Today; 2023 Dec; 28(12):103807. PubMed ID: 37898421
[TBL] [Abstract][Full Text] [Related]
32. Farmers' Preferences for PES Contracts to Adopt Silvopastoral Systems in Southern Ecuador, Revealed Through a Choice Experiment.
Raes L; Speelman S; Aguirre N
Environ Manage; 2017 Aug; 60(2):200-215. PubMed ID: 28474210
[TBL] [Abstract][Full Text] [Related]
33. Production of high-quality marketing applications: strategies for biotechnology companies working with contract research organizations.
Hecker SJ; Preston C; Foote M
Biotechnol Annu Rev; 2003; 9():269-77. PubMed ID: 14650931
[TBL] [Abstract][Full Text] [Related]
34. 10 outsourcing myths that raise your risk.
Guy RA; Hill JR
Healthc Financ Manage; 2007 Jun; 61(6):66-72. PubMed ID: 17571710
[TBL] [Abstract][Full Text] [Related]
35. High-cost fears. With proper contracts and good relationship management, healthcare companies can achieve flexible, cost-effective outsourcing agreements.
Goostrey S; Desjardins D
Healthc Inform; 2006 Nov; 23(11):43-4. PubMed ID: 17144334
[No Abstract] [Full Text] [Related]
36. Negotiating with third party payers: one community pharmacy's experience.
Fridy K; DeHart RM; Monk-Tutor MR
J Am Pharm Assoc (Wash); 2002; 42(5):780-8. PubMed ID: 12269712
[TBL] [Abstract][Full Text] [Related]
37. The nature of outsourced preclinical research--the example of chemical synthesis.
Festel GW
Expert Opin Drug Discov; 2013 Sep; 8(9):1049-55. PubMed ID: 23725522
[TBL] [Abstract][Full Text] [Related]
38. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
Forster SP; Stegmaier J; Spycher R; Seeger S
Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
[TBL] [Abstract][Full Text] [Related]
39. The economics of priority review vouchers.
Dimitri N
Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
[TBL] [Abstract][Full Text] [Related]
40. Non-price competition in NHS secondary care contracting: empirical results.
Gray K; Bailey MF
J Health Organ Manag; 2008; 22(5):480-95. PubMed ID: 18959300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
